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worldwide and unprecedented decimation of the global 
economy. Despite its tremendous impact, the origin of SARS-
CoV-2 has remained mysterious and controversial. The natural 
origin theory, although widely accepted, lacks substantial 
support. The alternative theory that the virus may have come 
from a research laboratory is, however, strictly censored on 
peer-reviewed scientific journals. Nonetheless, SARS-CoV-2 
shows biological characteristics that are inconsistent with a 
naturally occurring, zoonotic virus. In this report, we describe 
the genomic, structural, medical, and literature evidence, 
which, when considered together, strongly contradicts the 
natural origin theory. The evidence shows that SARS-CoV2 
should be a laboratory product created by using bat 
coronaviruses ZC45 and/or ZXC21 as a template and/or 
backbone. Building upon the evidence, we further postulate a 
synthetic route for SARS-CoV-2, demonstrating that the 
laboratory-creation of this coronavirus is convenient and can 
be accomplished in approximately six months. Our work 
emphasizes the need for an independent investigation into the 
relevant research laboratories. It also argues for a critical look 
into certain recently published data, which, albeit problematic, 
was used to support and claim a natural origin of SARS-CoV-
2. From a public health perspective, these actions are 
necessary as knowledge of the origin of SARS-CoV-2 and of 
how the virus entered the human population are of pivotal 
importance in the fundamental control of the COVID-19 
pandemic as well as in preventing similar, future pandemics.  
i. Introduction 
OVID-19 has caused a world-wide pandemic, the 
scale and severity of which are unprecedented. 
Despite the tremendous efforts taken by the 
global community, management and control of this 
pandemic remains difficult and challenging.   
As a coronavirus, SARS-CoV-2 differs 
significantly from other respiratory and/or zoonotic 
viruses: it attacks multiple organs; it is capable of 




   
highly transmissible and significantly lethal in high-risk 
populations; it is well-adapted to humans since the very 
start of its emergence1; it is highly efficient in binding the 
human ACE2 receptor (hACE2), the affinity of which is 
greater than that associated with the ACE2 of any other 
potential host2,3.   
The origin of SARS-CoV-2 is still the subject of 
much debate. A widely cited Nature Medicine 
publication has claimed that SARS-CoV-2 most likely 
came from nature4. However, the article and its central 
conclusion are now being challenged by scientists from 
all over the world5-15. In addition, authors of this Nature 
Medicine article show signs of conflict of interests16,17, 
raising further concerns on the credibility of this 
publication.   
The existing scientific publications supporting a 
natural origin theory rely heavily on a single piece of 
evidence – a previously discovered bat coronavirus 
named RaTG13, which shares a 96% nucleotide 
sequence identity with SARS-CoV-218. However, the 
existence of RaTG13 in nature and the truthfulness of its 
reported sequence are being widely questioned6-9,19-21. It 
is noteworthy that scientific journals have clearly 
censored any dissenting opinions that suggest a non-
natural origin of SARS-CoV-28,22. Because of this 
censorship, articles questioning either the natural origin 
of SARS-CoV-2 or the actual existence of RaTG13, 
although of high quality scientifically, can only exist as 
preprints5-9,19-21 or other non-peer reviewed articles 
published on various online platforms10-13,23. 
Nonetheless, analyses of these reports have repeatedly 
pointed to severe problems and a probable fraud 
associated with the reporting of RaTG136,8,9,1921. 
Therefore, the theory that fabricated scientific data has 
been published to mislead the world’s efforts in tracing 
the origin of SARS-CoV-2 has become substantially 
convincing and is interlocked with the notion that SARS-
CoV-2 is of a non-natural origin.  
Consistent with this notion, genomic, structural, 
and literature evidence also suggest a non-natural origin 
of SARS-CoV-2. In addition, abundant literature 
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Figure 1: Genomic sequence analysis reveals that bat coronavirus ZC45 is the closest match to SARS-CoV-2. Top: 
genomic organization of SARS-CoV-2 (2019-nCoV WIV04). Bottom: similarity plot based on the full-length genome of 
2019-nCoV WIV04. Full-length genomes of SARS-CoV BJ01, bat SARSr-CoV WIV1, bat SARSr-CoV HKU3-1, bat 
coronavirus ZC45 were used as reference sequences. 
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indicates that gain-of-function research has long 
advanced to the stage where viral genomes can be 
precisely engineered and manipulated to enable the 
creation of novel coronaviruses possessing unique 
properties. In this report, we present such evidence and 
the associated analyses. Part 1 of the report describes 
the genomic and structural features of SARS-CoV2, the 
presence of which could be consistent with the theory 
that the virus is a product of laboratory modification 
beyond what could be afforded by simple serial viral 
passage. Part 2 of the report describes a highly 
probable pathway for the laboratory creation of SARS-
CoV-2, key steps of which are supported by evidence 
present in the viral genome. Importantly, part 2 should 
be viewed as a demonstration of how SARS-CoV-2 
could be conveniently created in a laboratory in a short 
period of time using available materials and well-
documented techniques. This report is produced by a 
team of experienced scientists using our combined 
expertise in virology, molecular biology, structural 
biology, computational biology, vaccine development, 
and medicine. 
a) Has SARS-CoV-2 been subjected to in vitro 
manipulation?  
We present three lines of evidence to support 
our contention that laboratory manipulation is part of the 
history of SARS-CoV-2:  
i. The genomic sequence of SARS-CoV-2 is 
suspiciously similar to that of a bat coronavirus 
discovered by military laboratories in the Third 
Military Medical University (Chongqing, China) and 
the Research Institute for Medicine of Nanjing 
Command (Nanjing, China). 
ii. The receptor-binding motif (RBM) within the Spike 
protein of SARS-CoV-2, which determines the host 
specificity of the virus, resembles that of SARS-CoV 
from the 2003 epidemic in a suspicious manner. 
Genomic evidence suggests that the RBM has been 
genetically manipulated.
iii. SARS-CoV-2 contains a unique furin-cleavage site in 
its Spike protein, which is known to greatly enhance 
viral infectivity and cell tropism. Yet, this cleavage 
site is completely absent in this particular class of 
coronaviruses found in nature. In addition, rare 
codons associated with this additional sequence 
suggest the strong possibility that this furin-
cleavage site is not the product of natural evolution 
and could have been inserted into the SARS-CoV-2 
genome artificially by techniques other than simple 
serial passage or multi-strain recombination events 
inside co-infected tissue cultures or animals. 
i. Genomic sequence analysis reveals that ZC45, or 
a closely related bat coronavirus, should be the 
backbone used for the creation of SARS-CoV-2 
The structure of the ~30,000 nucleotides-long 
SARS-CoV-2 genome is shown in Figure 1. Searching 
the NCBI sequence database reveals that, among all 
known coronaviruses, there were two related bat 
coronaviruses, ZC45 and ZXC21, that share the highest 
sequence identity with SARS-CoV-2 (each bat 
coronavirus is ~89% identical to SARS-CoV-2 on the 
nucleotide level).  Similarity between the genome of 
SARS-CoV-2 and those of representative β
coronaviruses is depicted in Figure 1. ZXC21, which is 
97% identical to and shares a very similar profile with 
ZC45, is not shown. Note that the RaTG13 virus is 
excluded from this analysis given the strong evidence 
suggesting that its sequence may have been fabricated 
and the virus does not exist in nature2,6-9. 
   
 
Orf8 is an accessory protein, the function of 
which is largely unknown in most coronaviruses, 
although recent data suggests that Orf8 of SARS-CoV-2 
mediates the evasion of host adaptive immunity by 
down regulating MHC-I24. Normally, Orf8 is poorly 
conserved in coronaviruses25. Sequence blast indicates 
that, while the Orf8 proteins of ZC45/ZXC21 share a 
94.2% identity with SARS-CoV-2 Orf8, no other 
coronaviruses share more than 58% identity with SARS-
CoV-2 on this particular protein. The very high homology 
here on the normally poorly conserved Orf8 protein is 
highly unusual.  
 
Figure 2: Sequence alignment of the E proteins from different β coronaviruses demonstrates the E protein’s 
permissiveness and tendency toward amino acid mutations. A. Mutations have been observed in different strains of 
SARS-CoV. GenBank accession numbers: SARS_GD01: AY278489.2, SARS_ExoN1: ACB69908.1, SARS_TW_GD1: 
AY451881.1, SARS_Sino1_11: AY485277.1. B. Alignment of E proteins from related bat coronaviruses indicates its 
tolerance of mutations at multiple positions. GenBank accession numbers: Bat_AP040581.1: APO40581.1, 
RsSHC014: KC881005.1, SC2018: MK211374.1, Bat_NP_828854.1: NP_828854.1, BtRs-BetaCoV/HuB2013: 
AIA62312.1, BM48-31/BGR/2008: YP_003858586.1. C. While the early copies of SARS-CoV-2 share 100% identity on 
the E protein with ZC45 and ZXC21, sequencing data of SARS-CoV2 from April 2020 indicates that mutation has 
occurred at multiple positions. Accession numbers of viruses: Feb_11: MN997409, ZC45: MG772933.1, ZXC21: 
MG772934, Apr_13: MT326139, Apr_15_A: MT263389, Apr_15_B: MT293206, Apr_17: MT350246. Alignments were 
done using the MultAlin web server (http://multalin.toulouse.inra.fr/multalin/). 
The coronavirus E protein is a structural protein, 
which is embedded in and lines the interior of the 
membrane envelope of the virion26. The E protein is 
tolerant of mutations as evidenced in both SARS (Figure 
2A) and related bat coronaviruses (Figure 2B). This 
tolerance to amino acid mutations of the E protein is 
further evidenced in the current SARS-CoV-2 pandemic. 
After only a short two-month spread of the virus since its 
outbreak in humans, the E proteins in SARS-CoV-2 have 
already undergone mutational changes. Sequence data 
obtained during the month of April reveals that 
mutations have occurred at four different locations in 
different strains (Figure 2C). Consistent with this finding, 
sequence blast analysis indicates that, with the 
exception of SARS-CoV-2, no known coronaviruses 
share 100% amino acid sequence identity on the E 
protein with ZC45/ZXC21 (suspicious coronaviruses 
published after the start of the current pandemic are 
excluded18,27-31). Although 100% identity on the E protein 
has been observed between SARS-CoV and certain 
SARS-related bat coronaviruses, none of those pairs 
simultaneously share over 83% identity on the Orf8 
protein32. Therefore, the 94.2% identity on the Orf8 
protein, 100% identity on the E protein, and the overall 
genomic/amino acid-level resemblance between SARS-
CoV-2 and ZC45/ZXC21 are highly unusual. Such 
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When SARS-CoV-2 and ZC45/ZXC21 are 
compared on the amino acid level, a high sequence 
identity is observed for most of the proteins. The 
Nucleocapsid protein is 94% identical. The Membrane 
protein is 98.6% identical. The S2 portion (2nd half) of 
the Spike protein is 95% identical. Importantly, the
Orf8protein is 94.2% identical and the E protein is 100% 
identical.
evidence, when considered together, is consistent with 
a hypothesis that the SARS-CoV-2 genome has an 
origin based on the use of ZC45/ZXC21 as a backbone 
and/or template for genetic gain-of-function 
modifications.   
Importantly, ZC45 and ZXC21 are bat corona 
viruses that were discovered (between July 2015 and 
February 2017), isolated, and characterized by military 
research laboratories in the Third Military 
MedicalUniversity (Chongqing, China) and the Research 
Institute for Medicine of Nanjing Command (Nanjing, 
China). The data and associated work were published in 
201833,34. Clearly, this backbone/template, which is 
essential for the creation of SARS-CoV-2, exists in these 
and other related research laboratories.  
What strengthens our contention further is the 
published RaTG13 virus18, the genomic sequence of 
which is reportedly 96% identical to that of SARS-CoV-2. 
While suggesting a natural origin of SARSCoV-2, the 
RaTG13 virus also diverted the attention of both the 
scientific field and the general public away from 
ZC45/ZXC214,18. In fact, a Chinese BSL-3 lab (the 
Shanghai Public Health Clinical Centre), which 
published a Nature article reporting a conflicting close 
phylogenetic relationship between SARSCoV-2 and 
ZC45/ZXC21 rather than with RaTG1335, was quickly 
shut down for “rectification”36. It is believed that the 
researchers of that laboratory were being punished for 
having disclosed the SARS-CoV2—ZC45/ZXC21 
connection. On the other hand, substantial evidence has 
accumulated, pointing to severe problems associated 
with the reported sequence of RaTG13 as well as 
questioning the actual existence of this bat virus in 
nature6,7,19-21. A very recent publication also indicated 
that the receptor-binding domain (RBD) of the RaTG13’s 
Spike protein could not bind ACE2 of two different types 
of horseshoe bats (they closely relate to the horseshoe 
bat R. affinis, RaTG13’s alleged natural host)2, 
implicating the inability of RaTG13 to infect horseshoe 
bats. This finding further substantiates the suspicion that 
the reported sequence of RaTG13 could have been 
fabricated as the Spike protein encoded by this 
sequence does not seem to carry the claimed function. 
The fact that a virus has been fabricated to shift the 
attention away from ZC45/ZXC21 speaks for an actual 
role of ZC45/ZXC21 in the creation of SARS-CoV-2.   
ii. The receptor-binding motif of SARS-CoV-2 Spike 
cannot be born from nature and should have been 
created through genetic engineering 
The Spike proteins decorate the exterior of the 
coronavirus particles. They play an important role in 
infection as they mediate the interaction with host cell 
receptors and thereby help determine the host range 
and tissue tropism of the virus. The Spike protein is split 
receptor. In both SARS-CoV and SARS-CoV-2 infections, 
the host cell receptor is hACE2. Within S1, a segment of 
around 70 amino acids makes direct contacts with 
hACE2 and is correspondingly named the receptor-
binding motif (RBM) (Figure 3C). In SARS-CoV and 
SARS-CoV-2, the RBM fully determines the interaction 
with hACE2. The C-terminal half of the Spike protein is 
named S2. The main function of S2 includes maintaining 
trimer formation and, upon successive protease 
cleavages at the S1/S2 junction and a downstream S2’ 
position, mediating membrane fusion to enable cellular 
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into two halves (Figure 3). The front or N-terminal half is 
named S1, which is fully responsible for binding the host 
Figure 3: Structure of the SARS Spike protein and how it binds to the hACE2 receptor. Pictures were generated 
based on PDB ID: 6acj37. A) Three spike proteins, each consisting of a S1 half and a S2 half, form a trimer. B) The S2 
halves (shades of blue) are responsible for trimer formation, while the S1 portion (shades of red) is responsible for 
binding hACE2 (dark gray). C) Details of the binding between S1 and hACE2. The RBM of S1, which is important and 
sufficient for binding, is colored in orange. Residues within the RBM that are important for either hACE2 interaction or 
protein folding are shown as sticks (residue numbers follow the SARS Spike sequence).  
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Figure 4: Sequence alignment of the spike proteins from relevant coronaviruses. Viruses being compared include 
SARS-CoV-2 (Wuhan-Hu-1: NC_045512, 2019-nCoV_USA-AZ1: MN997409), bat coronaviruses (Bat_CoV_ZC45: 
MG772933, Bat_CoV_ZXC21: MG772934), and SARS coronaviruses (SARS_GZ02: AY390556, SARS: 
NC_004718.3). Region marked by two orange lines is the receptor-binding motif (RBM), which is important for 
interaction with the hACE2 receptor. Essential residues are additionally highlighted by red sticks on top. Region 
marked by two green lines is a furin-cleavage site that exists only in SARS-CoV-2 but not in any other lineage B β 
coronavirus.  
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Similar to what is observed for other viral 
proteins, S2 of SARS-CoV-2 shares a high sequence 
identity (95%) with S2 of ZC45/ZXC21. In stark contrast, 
between SARS-CoV-2 and ZC45/ZXC21, the S1 protein, 
which dictates which host (human or bat) the virus can 
infect, is much less conserved with the amino acid 
sequence identity being only 69%.   
Figure 4 shows the sequence alignment of the 
Spike proteins from six β coronaviruses. Two are viruses 
isolated from the current pandemic (Wuhan-Hu-1, 2019-
nCoV_USA-AZ1); two are the suspected template 
viruses (Bat_CoV_ZC45, Bat_CoV_ZXC21); two are 
SARS coronaviruses (SARS_GZ02, SARS). The RBM is 
highlighted in between two orange lines. Clearly, despite 
the high sequence identity for the overall genomes, the 
RBM of SARS-CoV-2 differs significantly from those of 
ZC45 and ZXC21. Intriguingly, the RBM of SARS-CoV-2 
resembles, on a great deal, the RBM of SARS Spike. 
Although this is not an exact “copy and paste”, careful 
examination of the Spike-hACE2 structures37,38 reveals 
that all residues essential for either hACE2 binding or 
protein folding (orange sticks in Figure 3C and what is 
highlighted by red short lines in Figure 4) are “kept”. 
Most of these essential residues are precisely 
preserved, including those involved in disulfide bond 
formation (C467, C474) and electrostatic interactions 
(R444, E452, R453, D454), which are pivotal for the 
structural integrity of the RBM (Figure 3C and 4). The 
few changes within the group of essential residues are 
 
 
As elaborated below, the way that SARS-CoV-2 
RBM resembles SARS-CoV RBM and the overall 
sequence conservation pattern between SARS-CoV-2 
and ZC45/ZXC21 are highly unusual. Collectively, this 
suggests that portions of the SARS-CoV-2 genome have 
not been derived from natural quasi-species viral 
particle evolution.   
If SARS-CoV-2 does indeed come from natural 
evolution, its RBM could have only been acquired in one 
of the two possible routes: 1) an ancient recombination 
event followed by convergent evolution or 2) a natural 
recombination event that occurred fairly recently.  
In the first scenario, the ancestor of SARS-CoV-
2, a ZC45/ZXC21-like bat coronavirus would have 
recombined and “swapped” its RBM with a coronavirus 
carrying a relatively “complete” RBM (in reference to 
SARS). This recombination would result in a novel 
ZC45/ZXC21-like coronavirus with all the gaps in its 
RBM “filled” (Figure 4). Subsequently, the virus would 
have to adapt extensively in its new host, where the 
ACE2 protein is highly homologous to hACE2. Random 
mutations across the genome would have to have 
occurred to eventually shape the RBM to its current form 
– resembling SARS-CoV RBM in a highly intelligent 
manner. However, this convergent evolution process 
would also result in the accumulation of a large amount 
of mutations in other parts of the genome, rendering the 
overall sequence identity relatively low. The high 
sequence identity between SARS-CoV-2 and ZC45/ 
ZXC21 on various proteins (94-100% identity) do not 
support this scenario and, therefore, clearly indicates 
that SARS-CoV2 carrying such an RBM cannot come 
from a ZC45/ZXC21-like bat coronavirus through this 
convergent evolutionary route.  
In the second scenario, the ZC45/ZXC21-like 
coronavirus would have to have recently recombined 
and swapped its RBM with another coronavirus that had 
successfully adapted to bind an animal ACE2 highly 
homologous to hACE2. The likelihood of such an event 
depends, in part, on the general requirements of natural 
recombination: 1) that the two different viruses share 
significant sequence similarity; 2) that they must co-
infect and be present in the same cell of the same 
animal; 3) that the recombinant virus would not be 
cleared by the host or make the host extinct; 4) that the 
recombinant virus eventually would have to become 
stable and transmissible within the host species.   
In regard to this recent recombination scenario, 
the animal reservoir could not be bats because the 
ACE2 proteins in bats are not homologous enough to 
hACE2 and therefore the adaption would not be able to 
yield an RBM sequence as seen in SARS-CoV-2. This 
animal reservoir also could not be humans as the 
ZC45/ZXC21-like coronavirus would not be able to infect 
humans. In addition, there has been no evidence of any 
SARS-CoV-2 or SARS-CoV-2-like virus circulating in the 
human population prior to late 2019. Intriguingly, 
according to a recent bioinformatics study, SARS-CoV-2 
was well-adapted for humans since the start of the 
outbreak1.   
Only one other possibility of natural evolution 
remains, which is that the ZC45/ZXC21-like virus and a 
coronavirus containing a SARS-like RBM could have 
recombined in an intermediate host where the ACE2 
protein is homologous to hACE2. Several laboratories 
have reported that some of the Sunda pangolins 
smuggled into China from Malaysia carried 
coronaviruses, the receptor-binding domain (RBD) of 
which is almost identical to that of SARS-CoV-227-29,31. 
They then went on to suggest that pangolins are the 
likely intermediate host for SARS-CoV-227-29,31. However, 
recent independent reports have found significant flaws 
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in this data40-42. Furthermore, contrary to these     
almost exclusively hydrophobic “substitutions” (I428→L, 
L443→F, F460→Y, L472→F, Y484→Q), which should 
not affect either protein folding or the hACE2-interaction. 
At the same time, majority of the amino acid residues 
that are non-essential have “mutated” (Figure 4, RBM 
residues not labeled with short red lines). Judging from 
this sequence analysis alone, we were convinced early 
on that not only would the SARS-CoV-2 Spike protein 
bind hACE2 but also the binding would resemble, 
precisely, that between the original SARS Spike protein 























































































































Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification as a 
Biological Robot Rather than Natural Evolution and Delineation of Its Probable Synthetic Route
reports27-29,31, no coronaviruses have been detected in 
Sunda pangolin samples collected for over a decade in 
Malaysia and Sabah between 2009 and 201943. A recent 
study also showed that the RBD, which is shared 
between SARS-CoV-2 and the reported pangolin 
coronaviruses, binds to hACE2 ten times stronger than 
to the pangolin ACE22, further dismissing pangolins as 
the possible intermediate host. Finally, an in silico study, 
while echoing the notion that pangolins are not likely an 
intermediate host, also indicated that none of the animal 
ACE2 proteins examined in their study exhibited more 
favorable binding potential to the SARS-CoV-2 Spike 
protein than hACE2 did3. This last study virtually 
exempted all animals from their suspected roles as an 
intermediate host3, which is consistent with the 
observation that SARS-CoV-2 was well-adapted for 
humans from the start of the outbreak1. This is 
significant because these findings collectively suggest 
that no intermediate host seems to exist for SARS-CoV-
2, which at the very least diminishes the possibility of a 
recombinant event occurring in an intermediate host. 
Even if we ignore the above evidence that no 
proper host exists for the recombination to take place 
and instead assume that such a host does exist, it is still 
highly unlikely that such a recombination event could 
occur in nature.  
As we have described above, if natural 
recombination event is responsible for the appearance 
of SARSCoV-2, then the ZC45/ZXC21-like virus and a 
coronavirus containing a SARS-like RBM would have to 
recombine in the same cell by swapping the S1/RBM, 
which is a rare form of recombination. Furthermore, 
since SARS has occurred only once in human history, it 
would be at least equally rare for nature to produce a 
virus that resembles SARS in such an intelligent manner 
– having an RBM that differs from the SARS RBM only at 
a few non-essential sites (Figure 4). The possibility that 
this unique SARS-like coronavirus would reside in the 
same cell with the ZC45/ZXC21-like ancestor virus and 
the two viruses would recombine in the “RBM-
swapping” fashion is extremely low. Importantly, this, 
and the other recombination event described below in 
section 1.3 (even more impossible to occur in nature), 
would both have to happen to produce a Spike as seen 
in SARS-CoV-2.  
While the above evidence and analyses 
together appear to disapprove a natural origin of SARS-
CoV2’s RBM, abundant literature shows that gain-of-
function research, where the Spike protein of a 
coronavirus was specifically engineered, has repeatedly 
led to the successful generation of humaninfecting 
coronaviruses from coronaviruses of non-human 
origin44-47.  
Record also shows that research laboratories, 
for example, the Wuhan Institute of Virology (WIV), have 
successfully carried out such studies working with US 
researchers45 and also working alone47. In addition, the 
WIV has engaged in decades-long coronavirus 
surveillance studies and therefore owns the world’s 
largest collection of coronaviruses. Evidently, the 
technical barrier is non-existent for the WIV and other 
related laboratories to carry out and succeed in such 
Spike/RBM engineering and gain-of function research.  
Figure 5: Two restriction sites are present at either end of the RBM of SARS-CoV-2, providing convenience for 
replacing the RBM within the spike gene. A. Nucleotide sequence of the RBM of SARS-CoV-2 (Wuhan-Hu-1). An 
EcoRI site is found at the 5’-end of the RBM and a BstEII site at the 3’-end. B. Although these two restriction sites do 
not exist in the original spike gene of ZC45, they can be conveniently introduced given that the sequence 
discrepancy is small (2 nucleotides) in either case. C. Amino acid sequence alignment with the RBM region 
highlighted (color and underscore). The RBM highlighted in orange (top) is what is defined by the EcoRI and BstEII 
sites in the SARS-CoV-2 (Wuhan-Hu-1) spike. The RBM highlighted in magenta (middle) is the region swapped by 
Dr. Fang Li and colleagues into a SARS Spike backbone39. The RBM highlighted in blue (bottom) is from the Spike 
protein (RBM: 424-494) of SARS-BJ01 (AY278488.2), which was swapped by the Shi lab into the Spike proteins of 
different bat coronaviruses replacing the corresponding segments47.  
Strikingly, consistent with the RBM engineering 
theory, we have identified two unique restriction sites, 
EcoRI and BstEII, at either end of the RBM of the SARS-
CoV-2 genome, respectively (Figure 5A). These two 
sites, which are popular choices of everyday molecular 
cloning, do not exist in the rest of this spikegene. This 
particular settingmakes it extremely convenient to swap 
the RBM within spike, providing a quick way to test 
different RBMs and the corresponding Spike proteins.   
Such EcoRI and BstEII sites do not exist in the 
spike genes of other β coronaviruses, which strongly 
indicates that they were unnatural and were specifically 
introduced into this spike gene of SARS-CoV-2 for the 
convenience of manipulating the critical RBM. Although 
ZC45 spike also does not have these two sites (Figure 
5B), they can be introduced very easily as described in 
part 2 of this report.  
It is noteworthy that introduction of the EcoRI 
site here would change the corresponding amino acids 
from -WNT- to -WNS- (Figure 5AB). As far as we know, 
all SARS and SARS-like bat coronaviruses exclusively 
carry a T (threonine) residue at this location. SARS-CoV-
2 is the only exception in that this T has mutated to an S 
(serine), save the suspicious RaTG13 and pangolin 
coronaviruses published after the outbreak48.   
Once the restriction sites were successfully 
introduced, the RBM segment could be swapped 
conveniently using routine restriction enzyme digestion 
and ligation. Although alternative cloning techniques 
may leave no trace of genetic manipulation (Gibson 
assembly as one example), this oldfashioned approach 
could be chosen because it offers a great level of 
convenience in swapping this critical RBM.   
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Given that RBM fully dictates hACE2-binding 
and that the SARS RBM-hACE2 binding was fully 
characterized by high-resolution structures (Figure 
3)37,38, this RBM-only swap would not be any riskier than 
the full Spike swap. In fact, the feasibility of this RBM-
swap strategy has been proven39,47. In 2008, Dr. Zhengli 
Shi’s group swapped a SARS RBM into the Spike 
proteins of several SARS-like bat coronaviruses after 
introducing a restriction site into a codon-optimized 
spike gene (Figure 5C)47. They then validated the 
binding of the resulted chimeric Spike proteins with 
hACE2. Furthermore, in a recent publication, the RBM of 
SARS-CoV-2 was swapped into the receptor-binding 
domain (RBD) of SARSCoV, resulting in a chimeric RBD 
fully functional in binding hACE2 (Figure 5C)39. Strikingly, 
in bothcases, the manipulated RBM segments resemble 
almost exactly the RBM defined by the positions of 
theEcoRI and BstEII sites (Figure 5C). Although cloning 
details are lacking in both publications39,47, it is 
conceivable that the actual restriction sites may vary 
depending on the spike gene receiving the RBM 
insertion as well as the convenience in introducing 
unique restriction site(s) in regions of interest. It is 
noteworthy that the corresponding author of this recent 
publication39, Dr. Fang Li, has been an active 
collaborator of Dr. Zhengli Shi since 201049-53. Dr. Li was 
the first person in the world to have structurally 
elucidated the binding between SARS-CoV RBD and 
hACE238 and has been the leading expert in the 
structural understanding of Spike-ACE2 
interactions38,39,53-56. The striking finding of EcoRI and 
BstEII restriction sites at either end of the SARS-CoV-2 
RBM, respectively, and the fact that the same RBM 
region has been swapped both by Dr. Shi and by her 
long-term collaborator, respectively, using restriction 
enzyme digestion methods are unlikely a coincidence. 
Rather, it is the smoking gun proving that theRBM/Spike 
of SARS-CoV-2 is a product of genetic manipulation. 
Although it may be convenient to copy the exact 
sequence of SARS RBM, it would be too clear a sign of 
artificial design and manipulation. The more deceiving 
approach would be to change a few nonessential 
residues, while preserving the ones critical for binding. 
This design could be well-guided by the high-resolution 
structures (Figure 3)37,38. This way, when the overall 
sequence of the RBM would appear to be more distinct 
from that of the SARS RBM, the hACE2-binding ability 
would be well-preserved. We believe that all of the 
crucial residues (residues labeled with red sticks in 
Figure 4, which are the same residues shown in sticks in 
Figure 3C) should have been “kept”. As described 
earlier, while some should be direct preservation, some 
should have been switched to residues with similar 
properties, which would not disrupt hACE2-binding and 
may even strengthen the association further. 
Importantly, changes might have been made 
intentionally at non-essential sites, making it less like a 
“copy and paste” of the SARS RBM.  
iii. An unusual furin-cleavage site is present in the 
Spike protein of SARS-CoV-2 and is associated 
with the augmented virulence of the virus 
Another unique motif in the Spike protein of 
SARS-CoV-2 is a polybasic furin-cleavage site located at 
the S1/S2 junction (Figure 4, segment in between two 
green lines). Such a site can be recognized and cleaved 
by the furin protease. Within the lineage B of β 
coronaviruses and with the exception of SARSCoV-2, no 
viruses contain a furin-cleavage site at the S1/S2 
junction (Figure 6)57. In contrast, furincleavage site at 
this location has been observed in other groups of 
coronaviruses57,58. Certain selective pressure seems to 
be in place that prevents the lineage B of β 
coronaviruses from acquiring or maintaining such a site 
in nature.  
 
Figure 6: Furin-cleavage site found at the S1/S2 junction 
of Spike is unique to SARS-CoV-2 and absent in other 
lineage B β coronaviruses. Figure reproduced from 
Hoffmann, et al57.  
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As previously described, during the cell entry 
process, the Spike protein is first cleaved at the S1/S2 
junction. This step, and a subsequent cleavage 
downstream that exposes the fusion peptide, are both 
mediated by host proteases. The presence or absence 
of these proteases in different cell types greatly affects 
the cell tropism and presumably the pathogenicity of the 
viral infection. Unlike other proteases, furin protease is 
widely expressed in many types of cells and is present 
at multiple cellular and extracellular locations. 
Importantly, the introduction of a furin-cleavage site at 
the S1/S2 junction could significantly enhance the 
infectivity of a virus as well as greatly expand its cell 
tropism — a phenomenon well-documented in both 
influenza viruses and other coronaviruses59-65.   
If we leave aside the fact that no furin-cleavage 
site is found in any lineage B β coronavirus in nature and 
instead assume that this site in SARS-CoV-2 is a result 
of natural evolution, then only one evolutionary pathway 
is possible, which is that the furin-cleavage site has to 
be derived from a homologous recombination event. 
Specifically, an ancestor β coronavirus containing no 
furin-cleavage site would have to recombine with a 
closely related coronavirus that does contain a furin-
cleavage site.   
However, two facts disfavor this possibility. 
First, although some coronaviruses from other groups or 
lineages do contain polybasic furin-cleavage sites, none 
of them contains the exact polybasic sequence present 
in SARS-CoV-2 (-PRRAR/SVA-). Second, between SARS-
CoV-2 and any coronavirus containing a legitimate furin-
cleavage site, the sequence identity on Spike is no more 
than 40%66. Such a low level of sequence identity rules 
out the possibility of a successful homologous 
recombination ever occurring between the ancestors of 
these viruses. Therefore, the furin-cleavage site within 
the SARS-CoV-2 Spike protein is unlikely to be of natural 
origin and instead should be a result of laboratory 
modification.  
Consistent with this claim, a close examination 
of the nucleotide sequence of the furin-cleavage site in 
SARS-CoV-2 spike has revealed that the two 
consecutive Arg residues within the inserted sequence 
(PRR
Figure 7: Two consecutive Arg residues in the -PRRA- insertion at the S1/S2 junction of SARS-CoV-2 Spike are both 
coded by a rare codon, CGG. A FauI restriction site, 5’-(N)6 GCGGG-3’, is embedded in the coding sequence of the 
“inserted” PRRA segment, which may be used as a marker to monitor the preservation of the introduced furin-
cleavage site.   
A-) are both coded by the rare codon CGG (least 
used codon for Arg in SARS-CoV-2) (Figure 7)8. In fact, 
this CGGCGG arrangement is the only instance found in 
the SARS-CoV-2 genome where this rare codon is used 
in tandem. This observation strongly suggests that this 
furin-cleavage site should be aresult of genetic 
engineering. Adding to the suspicion, a FauI restriction 
site is formulated by the codon choices here, 
suggesting the possibility that the restriction fragment 
length polymorphism, a technique that a WIV lab is 
proficient at67, could have been involved. There, the 
fragmentation pattern resulted from FauI digestion could 
be used to monitor the preservation of the furin-
cleavage site in Spike as this furincleavage site is prone 
to deletions in vitro68,69. Specifically, RT-PCR on the spike 
gene of the recovered viruses from cell cultures or 
laboratory animals could be carried out, the product of 
which would be subjected to FauI digestion. Viruses 
retaining or losing the furin-cleavage site would then 
yield distinct patterns, allowing convenient tracking of 
the virus(es) of interest.  
In addition, although no known coronaviruses 
contain the exact sequence of -PRRAR/SVA- that is 
present in the SARS-CoV-2 Spike protein, a similar -
RRAR/AR- sequence has been observed at the S1/S2 
junction of the Spike protein in a rodent coronavirus, 
AcCoV-JC34, which was published by Dr. Zhengli Shi in 
201770. It is evident that the legitimacy of -RRAR- as a 
functional furin-cleavage site has been known to the WIV 
experts since 2017.  
The evidence collectively suggests that the 
furin-cleavage site in the SARS-CoV-2 Spike protein may 
not have come from nature and could be the result of 
genetic manipulation. The purpose of this manipulation 
could have been to assess any potential enhancement 
of the infectivity and pathogenicity of the laboratory-
made coronavirus59-64. Indeed, recent studies have 
confirmed that the furin-cleavage site does confer 
significant pathogenic advantages to SARS-CoV-257,68.   
iv. Discussion 
Evidence presented in this part reveals that 
certain aspects of the SARS-CoV-2 genome are 
extremely difficult to reconcile to being a result of natural 
evolution. The alternative theory we suggest is that the 
virus may have been created by using ZC45/ZXC21 bat 
coronavirus(es) as the backbone and/or template. The 
Spike protein, especially the RBM within it, should have 
been artificially manipulated, upon which the virus has 
acquired the ability to bind hACE2 and infect humans. 
This is supported by the finding of a unique restriction 
enzyme digestion site at either end of the RBM. An 
unusual furin-cleavage site may have been introduced 
and inserted at the S1/S2 junction of the Spike protein, 
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which contributes to the increased virulence and 
pathogenicity of the virus. These transformations have 
then staged the SARSCoV-2 virus to eventually become 
a highly-transmissible, onset-hidden, lethal, sequelae-
unclear, and massively disruptive pathogen.   
Evidently, the possibility that SARS-CoV-2 could 
have been created through gain-of-function 
manipulations at the WIV is significant and should be 
investigated thoroughly and independently.   
b) Delineation of a synthetic route of SARS-CoV-2  
In the second part of this report, we describe a 
synthetic route of creating SARS-CoV-2 in a laboratory 
setting. It is postulated based on substantial literature 
support as well as genetic evidence present in the 
SARS-CoV-2 genome. Although steps presented herein 
should not be viewed as exactly those taken, we believe 
that key processes should not be much different. 
Importantly, our work here should serve as a 
demonstration of how SARS-CoV-2 can be designed 
and created conveniently in research laboratories by 
following proven concepts and using well-established 
techniques.   
Importantly, research labs, both in Hong Kong 
and in mainland China, are leading the world in 
coronavirus research, both in terms of resources and on 
the research outputs. The latter is evidenced not only by 
the large number of publications that they have 
produced over the past two decades but also by their 
milestone achievements in the field: they were the first to 
identify civets as the intermediate host for SARS-CoV 
and isolated the first strain of the virus71; they were the 
first to uncover that SARS-CoV originated from bats72,73; 
they revealed for the first time the antibody-dependent 
enhancement (ADE) of SARS-CoV infections74; they 
have contributed significantly in understanding MERS in 
all domains (zoonosis, virology, and clinical studies)75-79; 
they made several breakthroughs in SARS-CoV-2 
research18,35,80. Last but not least, they have the world’s 
largest collection of coronaviruses (genomic sequences 
and live viruses). The knowledge, expertise, and 
resources are all readily available within the Hong Kong 
and mainland research laboratories (they collaborate 
extensively) to carry out and accomplish the work 
described below. 
 
Figure 8: Diagram of a possible synthetic route of the laboratory-creation of SARS-CoV-2 
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c) Possible scheme in designing the laboratory-
creation of the novel coronavirus 
In this sub-section, we outline the possible 
overall strategy and major considerations that may have 




Once they have chosen a template virus, they 
would first need to engineer, through molecular 
cloning,the Spike protein so that it can bind hACE2. The 
concept and cloning techniques involved in this 
manipulation have been well-documented in the 
literature44-46,84,86. With almost no risk of failing, the 
template bat virus could then be converted to a 
coronavirus that can bind hACE2 and infect humans44-46.   
Second, they would use molecular cloning to 
introduce a furin-cleavage site at the S1/S2 junction 
ofSpike. This manipulation, based on known 
knowledge60,61,65, would likely produce a strain of 
coronavirus that is a more infectious and pathogenic.   
Third, they would produce an ORF1b gene 
construct. The ORF1b gene encodes the polyprotein 
Orf1b, which is processed post-translationally to 
produce individual viral proteins: RNA-dependent RNA 
polymerase (RdRp), helicase, guanidine-N7 methyl 
transferase, uridylate-specific endoribonuclease, and 2’-
O-methyltransferase. All of these proteins are parts of 
the replication machinery of the virus. Among them, the 
RdRp protein is the most crucial one and is highly 
conserved among coronaviruses. Importantly, Dr. 
Zhengli Shi’s laboratory uses a PCR protocol, which 
amplifies a particular fragment of the RdRp gene, as 
their primary method to detect the presence of 
coronaviruses in raw samples (bat fecal swap, feces, 
etc). As a result of this practice, the Shi group has 
documented the sequence information of this short 
segment of RdRp for all coronaviruses that they have 
successfully detected and/or collected.  
Here, the genetic manipulation is less 
demanding or complicated because Orf1b is conserved 
and likely Orf1b from any β coronavirus would be 
competent enough to do the work. However, we believe 
that they would want to introduce a particular Orf1b into 
the virus for one of the two possible reasons:   
1. Since many phylogenetic analyses categorize 
coronaviruses based on the sequence similarity of 
the RdRp gene only18,31,35,83,87, having a different 
RdRp in the genome therefore could ensure that 
SARS-CoV-2 and ZC45/ZXC21 are separated into 
different groups/sub-lineages in phylogenetic 
studies. Choosing an RdRp gene, however, is 
convenient because the short RdRp segment 
sequence has been recorded for all coronaviruses 
ever collected/detected. Their final choice was the 
RdRp sequence from bat coronavirus 
RaBtCoV/4991, which was discovered in 2013. For 
RaBtCoV/4991, the only information ever published 
was the sequence of its short RdRp segment83, 
while neither its full genomic sequence nor virus 
isolation were ever reported. After amplifying the 
RdRp segment (or the whole ORF1b gene) of 
RaBatCoV/4991, they would have then used it for 
subsequent assembly and creation of the genome 
of SARS-CoV-2. Small changes in the RdRp 
sequence could either be introduced at the 
beginning (through DNA synthesis) or be generated 
viapassages later on. On a separate track, when 
they were engaged in the fabrication of the RaTG13 
sequence, they could have started with the short 
RdRp segment of RaBtCoV/4991 without 
introducing any changes to its sequence, resulting 
in a 100% nucleotide sequence identity between the 
two viruses on this short RdRp segment83. This 
RaTG13 virus could then be claimed to have been 
discovered back in 2013.  
2. The RdRp protein from RaBatCoV/4991 is unique in 
that it is superior thanRdRp from any other β 
coronavirus for developing antiviral drugs. RdRp 
has no homologs in human cells, which makes this 
essential viral enzyme a highly desirable target for 
antiviral development. As an example, Remedesivir, 
which is currently undergoing clinical trials, targets 
RdRp. When creating a novel and human-targeting 
virus, they would be interested in developing the 
antidote as well. Even though drug discovery like 
this may not be easily achieved, it is reasonable for 
them to intentionally incorporate a RdRp that is 
more amenable for antiviral drug development.  
Fourth, they would use reverse genetics to 
assemble the gene fragments of spike, ORF1b, and the 
rest of the template ZC45 into a cDNA version of the 
viral genome. They would then carry out in vitro 
transcription to obtain the viral RNA genome. 
Transfection of the RNA genome into cells would allow 
the recovery of live and infectious viruses with the 
desired artificial genome.  
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To engineer and create a human-targeting 
coronavirus, they would have to pick a bat coronavirus 
asthe template/backbone. This can be conveniently 
done because many research labs have been actively 
collecting bat coronaviruses over the past two 
decades32,33,70,72,81-85. However, this template virus ideally 
should not be one from Dr. Zhengli Shi’s collections, 
considering that she is widely known to have been 
engaged in gain-of-function studies on coronaviruses. 
Therefore, ZC45 and/or ZXC21, novel bat coronaviruses 
discovered and owned by military laboratories33, would 
be suitable as the template/backbone. It is also possible 
that these military laboratories had discovered other 
closely related viruses from the same location and kept 
some unpublished. Therefore, the actual template could 
be ZC45, or ZXC21, or a close relative of them. The 
postulated pathway described below would be the same 
regardless of which one of the three was the actual 
template.  
Fifth, they would carry out characterization and 
optimization of the virus strain(s) to improve the fitness, 
infectivity, and overall adaptation using serial passage in 
vivo. One or several viral strains that meet certain criteria 
would then be obtained as the final product(s). 
d) A postulated synthetic route for the creation of SARS-
CoV-2  
In this sub-section, we describe in more details 
how each step could be carried out in a laboratory 
setting using available materials and routine molecular, 
cellular, and virologic techniques. A diagram of this 
process is shown in Figure 8. We estimate that the 
whole process could be completed in approximately 6 
months.   
Step 1: Engineering the RBM of the Spike for hACE2-
binding (1.5 months) 
The Spike protein of a bat coronavirus is either 
incapable of or inefficient in binding hACE2 due to the 
missing of important residues within its RBM. This can 
be exemplified by the RBM of the template virus ZC45 
(Figure 4). The first and most critical step in the creation 
of SARS-CoV-2 is to engineer the Spike so that it 
acquires the ability to bind hACE2. As evidenced in the 
literature, such manipulations have been carried out 
repeatedly in research laboratories since 200844, which 
successfully yielded engineered coronaviruses with the 
ability to infect human cells44-46,88,89. Although there are 
many possible ways that one can engineer the Spike 
protein, we believe that what was actually undertaken 
was that they replaced the original RBM with a designed 
and possibly optimized RBM using SARS’ RBM as a 
guide. As described in part 1, this theory is supported 
by our observation that two unique restriction sites, 
EcoRI and BstEII, exist at either end of the RBM in the 
SARS-CoV-2 genome (Figure 5A) and by the fact that 
such RBM-swap has been successfully carried out by 
Dr. Zhengli Shi and by her long-term collaborator and 
structure biology expert, Dr. Fang Li39,47.  
Although ZC45 spike does not contain these 
two restriction sites (Figure 5B), they can be introduced 
very easily. The original spike gene would be either 
amplified with RT-PCR or obtained through DNA 
synthesis (some changes could be safely introduced to 
certain variable regions of the sequence) followed by 
PCR. The gene would then be cloned into a plasmid 
using restriction sites other than EcoRI and BstEII.  
Once in the plasmid, the spike gene can be 
modified easily. First, an EcoRI site can be introduced 
by converting the highlighted “gaacac” sequence 
(Figure 5B) to the desired “gaattc” (Figure 5A). The 
difference between them are two consecutive 
nucleotides. Using the commercially available Quik 
Change Site-Directed Mutagenesis kit, such a di-
nucleotide mutation can be generated in no more than 
one week. Subsequently, the BstEII site could be 
similarly introduced at the other end of the RBM. 
Specifically, the “gaatacc” sequence (Figure 5B) would 
be converted to the desired “ggttacc” (Figure 5A), which 
would similarly require a week of time.  
Once these restriction sites, which are unique 
within the spike gene of SARS-CoV-2, were successfully 
introduced, different RBM segments could be swapped 
in conveniently and the resulting Spike protein 
subsequently evaluated using established assays.   
As described in part 1, the design of an RBM 
segment could be well-guided by the high-resolution 
structures (Figure 3)37,38, yielding a sequence that 
resembles the SARS RBM in an intelligent manner. 
When carrying out the structure-guided design of the 
RBM, they would have followed the routine and 
generated a few (for example a dozen) such RBMs with 
the hope that some specific variant(s) may be superior 
than others in binding hACE2. Once the design was 
finished, they could have each of the designed RBM 
genes commercially synthesized (quick and very 
affordable) with an EcoRI site at the 5’-end and a BstEII 
site at the 3’-end. These novel RBM genes could then be 
cloned into the spike gene, respectively. The gene 
synthesis and subsequent cloning, which could be done 
in a batch mode for the small library of designed RBMs, 
would take approximately one month.   
These engineered Spike proteins might then be 
tested for hACE2-binding using the established 
pseudotype virus infection assays45,49,50. The engineered 
Spike with good to exceptional binding affinities would 
be selected. (Although not necessary, directed evolution 
could be involved here (error-prone PCR on the RBM 
gene), coupled with either an in vitro binding assay39,90 or 
a pseudotype virus infection assay45,49,50, to obtain an 
RBM that binds hACE2 with exceptional affinity.)  
Given the abundance of literature on Spike 
engineering44-46,84,86 and the available high-resolution 
structures of the Spike-hACE2 complex37,38, the success 
of this step would be very much guaranteed. By the end 
of this step, as desired, a novel spike gene would be 
obtained, which encodes a novel Spike protein capable 
of binding hACE2 with high affinity.  
Step 2: Engineering a furin-cleavage site at the S1/S2 
junction (0.5 month) 
The product from Step 1, a plasmid containing 
the engineered spike, would be further modified to 
include a furin-cleavage site (segment indicated by 
green lines in Figure 4) at the S1/S2 junction. This short 
stretch of gene sequence can be conveniently inserted 
using several routine cloning techniques, including Quik 
Change Site-Directed PCR60, overlap PCR followed by 
restriction enzyme digestion and ligation91, or Gibson 
assembly. None of these techniques would leave any 
trace in the sequence. Whichever cloning method was 
the choice, the inserted gene piece would be included in 
the primers, which would be designed, synthesized, and 
used in the cloning. This step, leading to a further 
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modified Spike with the furin-cleavage site added at the 
S1/S2 junction, could be completed in no more than two 
weeks.  
 
Unlike the engineering of Spike, no complicated 
design is needed here, except that the RdRp gene 
segment from RaBtCoV/4991 would need to be 
included. Gibson assembly could have been used here. 
In this technique, several fragments, each adjacent pair 
sharing 20-40 bp overlap, are combined together in one 
simple reaction to assemble a long DNA product. Two 
or three fragments, each covering a significant section 
of the ORF1b gene, would be selected based on known 
bat coronavirus sequences. One of these fragments 
would be the RdRp segment of RaBtCoV/499183. Each 
fragment would be PCR amplified with proper overlap 
regions introduced in the primers. Finally, all purified 
fragments would be pooled in equimolar concentrations 
and added to the Gibson reaction mixture, which, after a 
short incubation, would yield the desired ORF1b gene in 
whole.  
Step 4: Produce the designed viral genome using 
reverse genetics and recover live viruses (0.5 month) 
Reverse genetics have been frequently used in 
assembling whole viral genomes, including coronavirus 
genomes67,92-96. The most recent example is the 
reconstruction of the SARS-CoV-2 genome using the 
transformation-assisted recombination in yeast97. Using 
this method, the Swiss group assembled the entire viral 
genome and produced live viruses in just one week97. 
This efficient technique, which would not leave any trace 
of artificial manipulation in the created viral genome, has 
been available since 201798,99. In addition to the 
engineered spike gene (from steps 1 and 2) and the 
ORF1b gene (from step 3), other fragments covering the 
rest of the genome would be obtained either through 
RT-PCR amplification from the template virus or through 
DNA synthesis by following a sequence slightly altered 
from that of the template virus. We believe that the latter 
approach was more likely as it would allow sequence 
changes introduced into the variable regions of less 
conserved proteins, the process of which could be 
easily guided by multiple sequence alignments. The 
amino acid sequences of more conserved functions, 
such as that of the E protein, might have been left 
unchanged. All DNA fragments would then be pooled 
together and transformed into yeast, where the cDNA 
version of the SARS-CoV-2 genome would be 
assembled via transformation-assisted recombination. 
Of course, an alternative method of reverse genetics, 
one of which the WIV has successfully used in the 
past67, could also be employed67,92-96,100. Although some 
earlier reverse genetics approaches may leave 
restriction sites at where different fragments would be 
joined, these traces would be hard to detect as the 
exact site of ligation can be anywhere in the ~30kb 
genome. Either way, a cDNA version of the viral genome 
would be obtained from the reverse genetics 
experiment. Subsequently, in vitro transcription using the 
cDNA as the template would yield the viral RNA 
genome, which upon transfection into Vero E6 cells 
would allow the production of live viruses bearing all of 
the designed properties.  
Step 5: Optimize the virus for fitness and improve its 
hACE2-binding affinity in vivo (2.5-3 months) 
Virus recovered from step 4 needs to be further 
adapted undergoing the classic experiment – serial 
passage in laboratory animals101. This final step would 
validate the virus’ fitness and ensure its receptor 
oriented adaptation toward its intended host, which, 
according to the analyses above, should be human. 
Importantly, the RBM and the furin-cleavage site, which 
were introduced into the Spike protein separately, would 
now be optimized together as one functional unit. 
Among various available animal models (e.g. mice, 
hamsters, ferrets, and monkeys) for coronaviruses, 
hACE2 transgenic mice (hACE2-mice) should be the 
most proper and convenient choice here. This animal 
model has been established during the study of SARS-
CoV and has been available in the Jackson Laboratory 
for many years102-104.   
The procedure of serial passage is 
straightforward. Briefly, the selected viral strain from step 
4, a precursor of SARS-CoV-2, would be intranasally 
inoculated into a group of anaesthetized hACE2-mice. 
Around 2-3 days post infection, the virus in lungs would 
usually amplify to a peak titer. The mice would then be 
sacrificed and the lungs homogenized. Usually, the 
mouse-lung supernatant, which carries the highest viral 
load, would be used to extract the candidate virus for 
the next round of passage. After approximately 10~15 
rounds of passage, the hACE2-binding affinity, the 
infection efficiency, and the lethality of the viral strain 
would be sufficiently enhanced and the viral genome 
stabilized101. Finally, after a series of characterization 
experiments (e.g. viral kinetics assay, antibodies 
response assay, symptom observation and pathology 
examination), the final product, SARS-CoV-2, would be 
obtained, concluding the whole creation process. From 
this point on, this viral pathogen could be amplified 
(most probably using Vero E6 cells) and produced 
routinely.   
It is noteworthy that, based on the work done on 
SARS-CoV, the hACE2-mice, although suitable for 
SARS-CoV-2 adaptation, is not a good model to reflect 
the virus’ transmissibility and associated clinical 
symptoms in humans. We believe that those scientists 
might not have used a proper animal model (such as 
the golden Syrian hamster) for testing the transmissibility 
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Step 3: Obtain an ORF1b gene that contains the 
sequence of the short RdRp segment from 
RaBtCoV/4991 (1 month, yet can be carried out 
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of SARS-CoV-2 before the outbreak of COVID-19. If they 
had done this experiment with a proper animal model, 
the highly contagious nature of SARS-CoV-2 would be 
extremely evident and consequently SARS-CoV-2 would 
not have been described as “not causing human-to-
human transmission” at the start of the outbreak. 
We also speculate that the extensive laboratory-
adaptation, which is oriented toward enhanced 
transmissibility and lethality, may have driven the virus 
too far. As a result, SARS-CoV-2 might have lost the 
capacity to attenuate on both transmissibility and 
lethality during its current adaptation in the human 
population. This hypothesis is consistent with the lack of 
apparent attenuation of SARS-CoV-2 so far despite its 
great prevalence and with the observation that a recently 
emerged, predominant variant only shows improved 
transmissibility105-108.
Serial passage is a quick and intensive process, 
where the adaptation of the virus is accelerated. 
Although intended to mimic natural evolution, serial 
passage is much more limited in both time and scale. 
As a result, less random mutations would be expected 
in serial passage than in natural evolution. This is 
particularly true for conserved viral proteins, such as the 
E protein. Critical in viral replication, the E protein is a 
determinant of virulence and engineering of it may 
render SARS-CoV-2 attenuated109-111 Therefore, at the 
initial assembly stage, these scientists might have 
decided to keep the amino acid sequence of the E 
protein unchanged from that of ZC45/ZXC21. Due to the 
conserved nature of the E protein and the limitations of 
serial passage, no amino acid mutation actually 
occurred, resulting in a 100% sequence identity on the E 
protein between SARS-CoV-2 and ZC45/ZXC21. The 
same could have happened to the marks of molecular 
cloning (restriction sites flanking the RBM). Serial 
passage, which should have partially naturalized the 
SARS-CoV-2 genome, might not have removed all signs 
of artificial manipulation.  
Many questions remain unanswered about the 
origin of SARS-CoV-2. Prominent virologists have 
implicated in a Nature Medicine letter that laboratory 
escape, while not being entirely ruled out, was unlikely 
and that no sign of genetic manipulation is present in 
the SARS-CoV-2 genome4. However, here we show that 
genetic evidence within the spike gene of SARS-CoV-2 
genome (restriction sites flanking the RBM; tandem rare 
codons used at the inserted furin-cleavage site) does 
exist and suggests that the SARS-CoV-2 genome should 
be a product of genetic manipulation. Furthermore, the 
proven concepts, well-established techniques, and 
knowledge and expertise are all in place for the 
convenient creation of this novel coronavirus in a short 
period of time. 
Motives aside, the following facts about SARS-
CoV-2 are well-supported:  
1. If it was a laboratory product, the most critical 
element in its creation, the backbone/template virus 
(ZC45/ZXC21), is owned by military research 
laboratories. 
2. The genome sequence of SARS-CoV-2 has likely 
undergone genetic engineering, through which the 
virus has gained the ability to target humans with 
enhanced virulence and infectivity. 
3. The characteristics and pathogenic effects of SARS-
CoV-2 are unprecedented. The virus is highly 
transmissible, onset-hidden, multi-organ targeting, 
sequelae-unclear, lethal, and associated with 
various symptoms and complications. 
4. SARS-CoV-2 caused a world-wide pandemic, taking 
millions of lives and shutting down the global 
economy. It has a destructive power like no other.   
Judging from the evidence that we and others 
have gathered, we believe that finding the origin of 
SARS-CoV-2 should involve an independent audit of the 
WIV P4 laboratories and the laboratories of their close 
collaborators. Such an investigation should have taken 
place long ago and should not be delayed any further.  
We also note that in the publication of the 
chimeric virus SHC015-MA15 in 2015, the attribution of 
funding of Zhengli Shi by the NIAID was initially left out. 
It was reinstated in the publication in 2016 in a 
corrigendum, perhaps after the meeting in January 2016 
to reinstate NIH funding for gain-of-function research on 
viruses. This is an unusual scientific behavior, which 
needs an explanation for.  
What is not thoroughly described in this report 
is the various evidence indicating that several 
coronaviruses recently published (RaTG1318, RmYN0230, 
and several pangolin coronaviruses27-29,31) are highly 
suspicious and likely fraudulent. These fabrications 
would serve no purpose other than to deceive the 
scientific community and the general public so that the 
true identity of SARS-CoV-2 is hidden. Although 
exclusion of details of such evidence does not alter the 
conclusion of the current report, we do believe that 
these details would provide additional support for our 
contention that SARS-CoV-2 is a laboratory-enhanced 
virus and a product of gain-of-function research. A 
follow-up report focusing on such additional evidence is 
now being prepared and will be submitted shortly.   
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